GSK reports early trial results for Mo-Rez in ovarian and endometrial cancers
The Facts
- GSK reported early-stage clinical results for mocertatug rezetecan, also known as Mo-Rez, in gynecological cancers.
- In platinum-resistant ovarian cancer, Mo-Rez showed an objective response rate of 62% in the reported early data.
- In endometrial cancer, Mo-Rez showed an objective response rate of 67% in the reported early data.
- The reported response metric referred to patients whose tumors shrank by at least 30%, and in some coverage was described as tumors shrinking or disappearing.
- Mo-Rez is an antibody-drug conjugate, a type of targeted cancer therapy.
- GSK plans to move Mo-Rez into late-stage testing, with five phase 3 trials planned.
Context
What is Mo-Rez?
Mo-Rez is GSK's name for mocertatug rezetecan, an experimental antibody-drug conjugate being developed for cancers including ovarian and endometrial cancer London South East,Financial Times News.
What do the 62% and 67% results mean?
They refer to objective response rates in the early trial: the share of patients whose tumors met the study's threshold for a meaningful response, defined in Reuters and FT coverage as at least a 30% reduction in tumor size Yahoo! Finance,Financial Times News.
What happens next for the drug?
GSK said it plans to advance Mo-Rez into late-stage development, with five phase 3 trials planned this year Bloomberg Business,London South East,Financial Times News.
The receipts — all 16 sources
Wire services (4)
Independent coverage (12)
Facts first. Then every angle.
The day’s biggest stories in one short brief — the facts everyone agrees on, then the competing values behind the headlines. Free in your inbox.